人福医药：控股子公司获药物临床试验批准通知书

Core Viewpoint - Yifan Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, which are primarily used to treat diabetic peripheral neuropathy (DPN) related neuropathic pain and postherpetic neuralgia (PHN) [1] Company Summary - Yifan Pharmaceutical's subsidiary, Yichang Renfu, has been granted a clinical trial approval notice for Pregabalin sustained-release tablets [1] - The drug is aimed at addressing significant medical needs in the treatment of DPN and PHN, indicating potential market opportunities for the company [1]